Filtered By:
Source: Cancer Research
Cancer: Colon Cancer
This page shows you your search results in order of date.
Order by Relevance | Date
Total 53 results found since Jan 2013.
Abstract B16: Activation of NRF2 and adaptive resistance to chemotherapy
Nuclear factor-erythroid-2-related factor 2 (NRF2), a member of the cap ‘n’ collar family of bZIP transcription factors, confers protection against oxidative and electrophilic stress. NRF2 is of great interest in cancer research, due to its role in response to chemotherapy, including the class of drugs targeting thymidylate synthase (TYMS). It has long been known that inhibition of TYMS leads to depletion of thymidine levels and the onset of programmed cell death, deriving from the enzyme's function as the sole de novo source of thymidine for DNA replication and repair. Exposing cells to TYMS inhibitors such as fluorop...
Source: Cancer Research - January 30, 2017 Category: Cancer & Oncology Authors: Sarah A. Clinton, Karen W. Barbour, Franklin G. Berger Tags: New Therapeutic Approaches to Colorectal Cancer Source Type: research
Abstract 35: Diacylglycerol kinase zeta-mediated regulation of mTOR and SREBP-1 offers new opportunities for cancer management
Diacylglycerol (DAG) and phosphatidic acid (PA) are two lipids that lie at the core of several metabolic and signaling pathways, which allows integrated control of cell growth and nutrient sensing with cell metabolism. Diacylglycerol kinases (DGK) are a family of enzymes that balance the levels of both lipids. Some DGK isoforms, mainly DGKα, have been recently suggested as potential targets for cancer treatment (Dominguez et al, 2013; Torres-Ayuso et al, 2014). Previous observations from us indicate that the DGKζ isoform contributes the most to DGK activity in cancer cells, and DGKζ-derived PA is required for mTOR activ...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Torres-Ayuso, P., Jones, D., Tello-Lafoz, M., Avila-Flores, A., Merida, I. Tags: Molecular and Cellular Biology Source Type: research
Abstract 905: Influence of high fat diet and APC status on epigenetic regulation of FXR in colon cells
We examined the effects on CpG pmethylation of Fxr, and expression of FXR, peroxisome-proliferator activated receptor-gamma (PPARγ), and cyclooxygenase-2 (COX-2) mRNA. Also, we studied the influence of APC status on CpG methylation of the Fxr gene, and expression of FXR, ileal bile acid-binding protein (IBABP), small heterodimer partner (SHP), and COX-2 mRNA in normal colonic mucosa and colon tumors from APCMin/+ mice. Mice fed the HFD had reduced (60%) Fxr promoter methylation and increased (2∼3-fold) FXR, COX-2, and PPARγ mRNA levels. Conversely, APC-deficiency was associated with constitutive hypermethylation of the...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Selmin, O. I., Lyon, A. M., Fang, C., Doetschman, T. C., Thompson, P. A., Martinez, J. D., Smith, J., Lance, P. M., Romagnolo, D. F. Tags: Prevention Research Source Type: research
Abstract LB-136: The role of ER chaperone GRP94 in endometrial cancer progression
This study expands our understanding of GRP94 function in the progression of solid tumors and provides the first evidence that GRP94 could be a target for combating endometrial cancer.Citation Format: Jieli Shen, Yvonne G. Lin, Louis Dubeau, Amy S. Lee. The role of ER chaperone GRP94 in endometrial cancer progression. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr LB-136. doi:10.1158/1538-7445.AM2015-LB-136
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Shen, J., Lin, Y. G., Dubeau, L., Lee, A. S. Tags: Tumor Biology Source Type: research
Abstract 2958: Discovering therapeutic epigenetic targets using whole genome siRNA screening
Conclusions: A whole genome siRNA screen in combination with the DNMT inhibitor decitabine identified many new target genes that might be epigenetic regulators and potential targets for drug development.Citation Format: Yasuyuki Okamoto, Woonbok Chung, Judith Garriga, Jaroslav Jelinek, Jean-Pierre J. Issa. Discovering therapeutic epigenetic targets using whole genome siRNA screening. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 2958. doi:10.1158/1538-7445.AM2015-2958
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Okamoto, Y., Chung, W., Garriga, J., Jelinek, J., Issa, J.-P. J. Tags: Molecular and Cellular Biology Source Type: research
Abstract 1443: BMP-2 induces motility and invasiveness of colon cancer through upregulation of cancer stem cell
In this study, we investigated the function of BMP-2 and relevance BMP-2 and CSCs in Colon cancer cells.First, We compared the endogenous protein level of parental and spheroid cells by western blotting. The spheroid cells showed higher level of EMT(Epithelial mesenchymal transition) markers N-Cadherin and Snail, CSC markers (EpCAM and CD133), and p Smad1/5 known BMP-2 downstream than the corresponding parental cells. Then expression of EpCAM and CD133 was confirmed by flow cytometry. We found that BMP-2 plays a key role in Cancer stem cell. To determine function of BMP-2 in Colon cancer cells, we stimulated the colon canc...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kim, B. R., Kim, J. L., Park, S. H., Jeoung, Y. A., Lee, S. I., Min, B.-W., Oh, S. C. Tags: Tumor Biology Source Type: research
Abstract 159: LncRNA RoR enhances the c-Myc mRNA stability in colon cancer
Conclusion: It is well known that c-Myc mRNA has a very short half-life and regulation of c-Myc mRNA stability is complex. Our results suggest a novel mechanism of regulation of c-Myc mRNA stability involving lncRNA-RoR, hnRNP U and hnRNP D.Citation Format: Jianguo Huang. LncRNA RoR enhances the c-Myc mRNA stability in colon cancer. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 159. doi:10.1158/1538-7445.AM2015-159
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Huang, J. Tags: Molecular and Cellular Biology Source Type: research
Abstract 509: MicroRNA-140 suppresses the migration and invasion of colorectal cancer cell possibly through targeting Smad3
Conclusions miR-140 directly targets Smad3 in the post-transcriptional level. miR-140 suppresses the migrating and invasive potentials of CRC cell, possibly through down-regulating Smad3. The findings of this study suggest that miR-140 may have a unique potential as a possible biomarker candidate for tumor metastasis diagnosis and therapy.[Keywords] Colon neoplasms; microRNA-140; SMAD family member 3; Cell migration; Cell invasionCitation Format: Bo Song, Wenyue Zhao, Lianhong Li. MicroRNA-140 suppresses the migration and invasion of colorectal cancer cell possibly through targeting Smad3. [abstract]. In: Proceedings of th...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Song, B., Zhao, W., Li, L. Tags: Tumor Biology Source Type: research
Abstract 519: V-set and immunoglobulin domain containing 1 (VSIG1) demonstrates a tumor suppressive function in gastric cancer and non-small cell lung cancer
V-set and immunoglobulin domain containing 1 (VSIG1) was recently identified as a novel member of immunoglobulin-like cell-adhesion molecules. In human, VSIG1 has 2 transcript variant forms (variant 1 and variant 2). In normal tissues, VSIG1 was reported to be expressed predominantly in stomach and testis. In cancerous tissues, the expression of VSIG1 was shown to be restricted in a part of gastric, esophageal, and ovarian cancers. However, the role of VSIG1 in cancer progression has not been elucidated.VSIG1 protein expression in human normal tissues obtained at autopsy was detected by western blot analysis. We also analy...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Inoue, Y., Kurabe, N., Matsuura, S., Maeda, M., Kahyo, T., Igarashi, H., Funai, K., Niwa, H., Ogawa, H., Shinmura, K., Konno, H., Suda, T., Sugimura, H. Tags: Tumor Biology Source Type: research
Abstract 191: The role of microRNAs in the epigenetic silencing of CHD5, a tumor suppressor in neuroblastoma
Background: Neuroblastoma (NB) is a tumor of the sympathetic nervous system that is the most common extracranial solid tumor of childhood. NBs show remarkable clinical heterogeneity, and we, along with others, have identified different patterns of genomic change that underlie these diverse clinical behaviors. We first identified 1p deletion as a characteristic change in advanced stage NBs. CHD5, a tumor suppressor gene, was first identified because of its location on 1p36. However, mutation of the remaining allele of CHD5 is rare in these tumors. Therefore, it is likely that epigenetic mechanisms play important roles in CH...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Naraparaju, K., Kolla, V., Zhuang, T., Higashi, M., Blobel, G. A., Brodeur, G. M. Tags: Molecular and Cellular Biology Source Type: research
Abstract 2577: Aurora kinase inhibitors require PUMA to induce apoptosis and preferentially kill KRAS-mutant colon cancer cells
In this study, we found that inhibition of aurora kinases by siRNA or small-molecule inhibitors led to induction of p53-upregulated modulator of apoptosis (PUMA), a BH3-only BCL-2 family protein, in colorectal cancer cells irrespective of p53 status. Deficiency in PUMA increased polyploidy and abrogated mitochondria-mediated apoptosis induced by aurora kinase inhibitors. In response to aurora kinase inhibition, PUMA was directly activated by p65 through the canonical NF-kB pathway following AKT inhibition. Interestingly, aurora kinase inhibitors were found to preferentially kill KRAS-mutant colon cancer cells, which is ass...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Sun, J., Knickelbein, K., He, K., Chen, D., Yu, J., Zhang, L. Tags: Experimental and Molecular Therapeutics Source Type: research
Abstract 3088: Inhibition of CDK5 in colorectal cancer
Conclusions: CRC is the second leading cause of cancer related deaths mainly due to the metastatic disease. There are currently no effective pharmacologic treatments for CRC metastases. We have shown that CDK5 is upregulated and overexpressed in metastatic tumors when compared to primary colon tumors. Inhibition of CDK5 either by knockdown or through the use of small molecule inhibitors decreased downstream phosphorylation of specific targets and reduced expression of anti-apoptotic mediators. Together, these data suggest that CDK5 might play a role in metastatic CRC and we’ve identified a potential inhibitor, 20-223 whi...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Robb, C. M. Tags: Molecular and Cellular Biology Source Type: research
Abstract 3373: Identification of inflammation-related genes that regulate tumor-associated stemness using high-throughput siRNA screening
Cancer associated stem cells (CSCs) are considered to be responsible for tumor recurrence, metastasis as well as chemoresistance. These properties of tumor associated stemness are maintained by specialized microenvironment, including inflammation which is a key component of the tumor microenvironment. To study the relationship between inflammation and stemness of CSCs, here, we established a robust high-throughput RNAi screen platform for a global survey of inflammation-related genes affecting CSCs identity via alteration of Oct4 expression. Consequently, we found 72 novel genes from 1027 inflammation-related genes which c...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Xie, J., He, H., Chen, C., Bai, L., Wang, W., Liu, Y., Guo, J., Wu, P., Xiang, R., Luo, Y. Tags: Tumor Biology Source Type: research
Abstract 3415: PAICS is the prognostic marker in colorectal cancer patients with stage III
PAICS (Phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase) is an important bifunctional enzyme in de novo purine biosynthesis. It could be an attractive target for anticancer drug design, since rapidly dividing cancer cells rely on the purine through de novo pathway for synthesis of adenine and guanine, whereas normal cells favor the salvage pathway.Previous reports demonstrated that PAICS expression was up-regulated in ALL, lung cancer, and glioblastoma. In the present study, we first performed the comparison of PAICS mRNA expression between cancer tissue and normal colonic...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Kobayashi, Y., Kumamoto, K., Matsumoto, Y., Saito, M., Shimura, T., Takenoshita, S. Tags: Clinical Research (Excluding Clinical Trials) Source Type: research
Abstract 3164: Inflammasomes: fanning the flames of malignant mesothelioma initiation
Malignant mesothelioma (MM) is an aggressive and devastating cancer of the pleural/peritoneal mesothelium related to asbestos exposure. MM has a low survival rate (average: less than 12 months). Despite the causal relationship between asbestos and MM development, the exact mechanism by which asbestos causes MM is still poorly understood. There is an urgent need for the identification of mechanism(s) that may help in early detection and finding new treatment targets for prevention and treatment of MM.We have recently shown that asbestos exposure of human mesothelial cells (HMCs) leads to the activation of the NLRP3 inflamma...
Source: Cancer Research - August 2, 2015 Category: Cancer & Oncology Authors: Thompson, J. K., MacPherson, M. B., Beuschel, S. L., Shukla, A. Tags: Immunology Source Type: research
